• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Intrathecal tofersen for amyotrophic lateral sclerosis

byConstance Wu
August 28, 2020
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A 100mg treatment of tofersen was shown to decrease cerebrospinal fluid (CSF) superoxide dismutase 1 (SOD1) concentration in adults with amyotrophic lateral sclerosis (ALS) due to SOD1 mutations.

2. Lumbar puncture-related adverse events were shown to be present in most participants.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Amyotrophic lateral sclerosis, resulting from superoxide dismutase 1 (SOD1) mutations consist of approximately 2% of all cases with over 180 disease-causing mutations identified within the gene. Tofersen is an antisense oligonucleotide (ASO) which mediates SOD1 mRNA degradation, thereby, reducing the synthesis of SOD1 protein. However, the effect of tofersen dosing on patients diagnosed with ALS is unknown. As such, this study evaluated the safety, pharmacokinetics, and pharmacodynamics of tofersen in adults with SOD1 mutation mediated ALS. Intrathecal administration of tofersen was shown to significant reduce CSF SOD1 concentrations. While, this study was adequately powered to test the reduction of SOD1 concentration in the CSF, the study was not able to conclusively determine other clinical or biological measures due to its low power. Nonetheless, this study was strengthened by its extensive follow-up period and the additional analyses conducted on the exploratory nature of the efficacy outcomes.

Click to read the study, published today in NEJM

Relevant reading: Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

RELATED REPORTS

#VisualAbstract: Pridopidine Does Not Impact the Progression of Amyotrophic Lateral Sclerosis

#VisualAbstract: Fasudil is Tolerated and Effective in Amyotrophic Lateral Sclerosis

Neuroprosthesis enables conversational communication in amyotrophic lateral sclerosis

In-Depth [randomized controlled trial]: This randomized control trial enrolled 50 patients across 18 sites in the United States, Canada, and Western Europe. Patients enrolled in the study were adults over the age of 18 years with muscle weakness attributed to ALS, documented SOD1 mutation, and normal coagulation variables. The exclusion criteria for the study included participants currently taking or scheduled to start edaravone treatment. Patients were randomized in a 3:1 ratio to receive 20, 40, 60, or 100 mg tofersen doses or a placebo regimen. A single dose of the treatment was administered on days 1, 15, 29, 57, and 85. The primary outcome was treatment safety. The most common adverse events included headache (16 participants, 32%), procedural pain (16 participants, 32%), and post-lumbar puncture syndrome (13 participants, 26%). The difference in ratio of CSF SOD1 concentration between baseline and day 85 for the 20-mg group was 2 percentage points (95% confidence interval [CI], -18 to 27) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 40-mg group was -25 percentage points (95% CI, -40 to -5) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 60-mg group was -19 percentage points (95% CI, -35 to 2) compared to the placebo group. The difference in ratio of CSF SOD1 concentration for the 100-mg group was -33 percentage points (95% CI, -47 to -16) compared to the placebo group. Taken together, the 100-mg tofersen treatment was shown to decrease SOD1 concentration in adults with ALS with associated procedural-related adverse events.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ALSamyotrophic lateral sclerosisamyotrophic lateral sclerosis (ALS)tofersen
Previous Post

Better glucose control with closed-loop system in children with type 1 diabetes

Next Post

Addition of bevacizumab to standard therapy improves outcomes in metastatic colorectal cancer

RelatedReports

#VisualAbstract: Pridopidine Does Not Impact the Progression of Amyotrophic Lateral Sclerosis
StudyGraphics

#VisualAbstract: Pridopidine Does Not Impact the Progression of Amyotrophic Lateral Sclerosis

March 3, 2025
#VisualAbstract: Fasudil is Tolerated and Effective in Amyotrophic Lateral Sclerosis
StudyGraphics

#VisualAbstract: Fasudil is Tolerated and Effective in Amyotrophic Lateral Sclerosis

November 22, 2024
Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography
Chronic Disease

Neuroprosthesis enables conversational communication in amyotrophic lateral sclerosis

October 6, 2024
Quick Take: Amyotrophic Lateral Sclerosis versus Multifocal Motor Neuropathy: Utility of MR Neurography
Lifestyle

Consuming some polyunsaturated fatty acids may help slow the progression of amyotrophic lateral sclerosis

July 25, 2023
Next Post
Radiofrequency ablation of hepatic metastases in colorectal cancer linked with improved survival

Addition of bevacizumab to standard therapy improves outcomes in metastatic colorectal cancer

#VisualAbstract: Targeted intraoperative radiotherapy associated with similar outcomes as whole breast post-operative radiotherapy for breast cancer

#VisualAbstract: Targeted intraoperative radiotherapy associated with similar outcomes as whole breast post-operative radiotherapy for breast cancer

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes
  • Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes
  • Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.